Study Design

Study Design:

Patients Enrolled: 907
Mean Follow Up: 14 days
Mean Patient Age: <76 years
Female: 15

Patient Populations:

Patients <76 years of age presenting to the hospital within six hours of onset of symptoms with ST segment elevation of ≥0.1 mV in one or more limb lead or ≥0.2 mV in one or more precordial leads.

Exclusions:

Treatment with aspirin or nonsteroidal anti-inflammatory drugs during the past seven days, treatment with heparin or anticoagulation at the time of admission, previous coronary artery bypass grafting, severe congestive heart failure, or usual contraindications to thrombolysis

Primary Endpoints:

Coronary artery patency (TIMI II or III flow) at pre-discharge angiogram performed 7-14 days after admission

Secondary Endpoints:

Clinical markers of reperfusion at two hours defined as ≥50% reduction in subjective pain score, ≥50% reduction in ST-segment elevation, or a ≥100% increase in creatine kinase values from baseline; and cardiac events.

Drug/Procedures Used:

Patients with acute ST-segment elevation MI were randomized to receive either aspirin (250 mg IV bolus followed by 160 mg PO qd) or ridogrel (300 mg IV bolus followed by 300 mg PO bid). Patients first received 1.5 MU streptokinase infused over one hour, followed by administration of the study medication.

Concomitant Medications:

Additional use of aspirin or other antiplatelet medications was not allowed. Heparin was not allowed. All other medications were at the discretion of treating physician.